Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Core Viewpoint - Atara Biotherapeutics is under investigation for potential securities fraud following a significant decline in stock price and operational setbacks related to FDA responses and workforce reductions [1][2][3]. Company Developments - On January 16, 2025, Atara Biotherapeutics received a Complete Response Letter (CRL) from the FDA regarding its EBVALLO treatment, which was related to manufacturing concerns at a third-party facility [2]. - The FDA also placed a clinical hold on Atara's active Investigational New Drug applications, affecting both EBVALLO and the allogeneic CD19 CAR T therapy ATA3219, leading to a suspension of new patient enrollments [2]. - Following the CRL, Atara's stock price fell by $4.82, closing at$7.62, marking a 39% decline [3]. - On January 27, 2025, Atara announced plans to cut 50% of its workforce by June 2025 as part of its response to the ongoing challenges [3]. Legal and Regulatory Context - Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims on behalf of Atara's investors regarding potential securities fraud by the company and its officers [1]. - The firm has a strong reputation in handling securities class actions and derivative litigation across various jurisdictions [4].